Stock FOAMIX PHARMACEUTICALS LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Foamix Pharmaceuticals Ltd. Nasdaq

Equities

IL0011334385

Pharmaceuticals

Business Summary

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Managers

Managers TitleAgeSince
David Domzalski CEO
 Chief Executive Officer 58 20-02-29
Tyler Zeronda DFI
 Director of Finance/CFO 38 -
Iain Stuart CTO
 Chief Tech/Sci/R&D Officer 51 20-02-29
Mutya Harsch LAW
 General Counsel 50 20-02-29

Members of the board

Members of the board TitleAgeSince
Pat LePore BRD
 Director/Board Member 69 20-09-09
Steven Basta BRD
 Director/Board Member 59 14-12-31
Anthony Bruno BRD
 Director/Board Member 68 20-02-29
Elisabeth Sandoval BRD
 Director/Board Member 62 19-02-28
David Domzalski CEO
 Chief Executive Officer 58 20-02-29
Christine Borowski BRD
 Director/Board Member - Dec. 31
Sharon Barbari BRD
 Director/Board Member 70 20-02-29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 14,098,888 12,874,235 ( 91.31 %) 0 91.31 %

Shareholders

NameEquities%Valuation
Eventide Asset Management LLC
9.890 %
1,394,336 9.890 % 4 M $
Cormorant Asset Management LP
9.890 %
1,394,336 9.890 % 4 M $
Citadel Advisors LLC
8.377 %
1,181,088 8.377 % 4 M $
Citadel Advisors LLC (13f Subfiler)
8.377 %
1,181,088 8.377 % 4 M $
Access Industries, Inc. (New York)
7.920 %
1,116,585 7.920 % 3 M $
Soleus Capital Management LP
4.992 %
703,868 4.992 % 2 M $
Parkman Healthcare Partners LLC
4.940 %
696,470 4.940 % 2 M $
DSC Advisors LP
4.940 %
696,465 4.940 % 2 M $
Alphacentric Advisors LLC
4.739 %
668,151 4.739 % 2 M $
LifeSci Fund Management LLC
4.739 %
668,151 4.739 % 2 M $

Company contact information

VYNE Therapeutics, Inc.

685 Route 202/206 North Suite 301

08807, Bridgewater

+

http://www.vynetherapeutics.com
address Foamix Pharmaceuticals Ltd.

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.72% 659B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.68% 557B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.43% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.31% 322B
ABBVIE INC. Stock AbbVie Inc.
+9.16% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+6.30% 215B
NOVARTIS AG Stock Novartis AG
+4.80% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-6.05% 200B
PFIZER, INC. Stock Pfizer, Inc.
-8.77% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. VYNE Stock
  4. Stock
  5. Company Foamix Pharmaceuticals Ltd.